17-methyl-14α-morphinan-3-ol | 2616-02-6

• 分子结构分类: 有机化合物 - 生物碱及其衍生物 - 吗啡烷
• 英文名称: 17-methyl-14α-morphinan-3-ol
• 英文别名: (1R,9R,10S)-17-methyl-17-azatetracyclo[7.5.3.01,10.02,7]heptadeca-2(7),3,5-trien-4-ol
• CAS: 2616-02-6
• 化学式: C₁₇H₂₃NO
• 分子量: 257.376
• InChiKey: JAQUASYNZVUNQP-DJIMGWMZSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.1
• 重原子数：
  19
• 可旋转键数：
  0
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.65
• 拓扑面积：
  23.5
• 氢给体数：
  1
• 氢受体数：
  2

反应信息

• 作为产物：
  描述：

  alkaline earth salt of/the/ methylsulfuric acid 在 乙醇 、 铂 作用下， 生成 17-methyl-14α-morphinan-3-ol
  参考文献：
  名称：

  The Synthesis and Resolution of 3-Hydroxy-N-methylisomorphinan¹

  摘要：

  DOI：

  10.1021/ja01538a043

文献信息

• OXIME-SUBSTITUTED QUINOXALINE-TYPE PIPERIDINE COMPOUNDS AS ORL-1 MODULATORS
  申请人：Purdue Pharma L.P.

  公开号：US20150238485A1

  公开（公告）日：2015-08-27

  The present disclosure relates to Oxime-Substituted Quinoxaline-Type Piperidine Compounds, such as those of Formula (I): and the pharmaceutically acceptable salts and solvates thereof, wherein R 1 , R 2 , R 3 , R 4 , R 20 , R 21 , Q, Y 1 , Z, A, B, and a are as defined herein; compositions comprising an effective amount of an Oxime-Substituted Quinoxaline-Type Piperidine Compound, and methods to treat or prevent a condition, such as pain, comprising administering to an animal in need thereof an effective amount of an Oxime-Substituted Quinoxaline-Type Piperidine Compound.

  本公开涉及肟取代的喹噁啉型哌啶化合物，例如式（I）中的化合物及其药学上可接受的盐和溶剂化合物，其中R1、R2、R3、R4、R20、R21、Q、Y1、Z、A、B和a如本文所定义；包含有效量肟取代的喹噁啉型哌啶化合物的组合物，以及治疗或预防疾病（如疼痛）的方法，包括向需要治疗的动物中有效量的肟取代的喹噁啉型哌啶化合物。
• QUINAZOLIN-4(3H)-ONE-TYPE PIPERIDINE COMPOUNDS AND USES THEREOF
  申请人：TADESSE Dawit

  公开号：US20160002203A1

  公开（公告）日：2016-01-07

  The present disclosure relates to Quinazolin-4(3H)-one-Type Piperidine Compounds, such as those of Formula (I) and the pharmaceutically acceptable salts and solvates thereof, wherein R 1 , R 2 , R 3 , Q, Y 1 , Z, A, B, E, and a are as defined herein; compositions comprising an effective amount of a Quinazolin-4(3H)-one-Type Piperidine Compound, and methods to treat or prevent a condition, such as pain, comprising administering to an animal in need thereof an effective amount of a Quinazolin-4(3H)-one-Type Piperidine Compound.

  本公开涉及喹唑啉-4(3H)-酮型哌啶化合物，例如公式（I）中的化合物及其药学上可接受的盐和溶剂化物，其中R1、R2、R3、Q、Y1、Z、A、B、E和a的定义如本文所述；包含有效量喹唑啉-4(3H)-酮型哌啶化合物的组合物；以及通过向需要治疗或预防疾病，例如疼痛的动物施用有效量喹唑啉-4(3H)-酮型哌啶化合物的方法。
• Morphinan-derivatives for treating diabetes and related disorders
  申请人：Heinrich-Heine-Universität Düsseldorf

  公开号：EP2561866A1

  公开（公告）日：2013-02-27

  The invention relates to a morphinan-derivative according to general formula (I) wherein R1 and R2 are independently selected from -H, -R0, -C(=O)R0, -C(=O)OR0 or -C(=O)NHR0; wherein R0 is in each case independently selected from -C1-C6-alkyl, -aryl, -heteroaryl, -C1-C6-alkyl-aryl or -C1-C6-alkyl-heteroaryl, in each case independently unsubstituted or substituted; or its physiologically acceptable salt and/or stereoisomer, including mixtures thereof in all ratios, for use in the treatment of a disease or condition, where the disease or condition is insulin-dependent diabetes mellitus, non-insulin-dependent diabetes mellitus, obesity, neuropathy and/or nephropathy.

  本发明涉及符合通式 (I) 的吗啡南衍生物 其中 R1和R2独立地选自-H、-R0、-C(＝O)R0、-C(＝O)OR0或-C(＝O)NHR0；其中R0在每种情况下独立地选自-C1-C6-烷基、-芳基、-杂芳基、-C1-C6-烷基-芳基或-C1-C6-烷基-杂芳基，在每种情况下独立地未取代或取代； 或其生理上可接受的盐和/或立体异构体，包括其各种比例的混合物，用于治疗疾病或病症，其中疾病或病症为胰岛素依赖型糖尿病、非胰岛素依赖型糖尿病、肥胖症、神经病变和/或肾病。
• Pharmaceutical compositions and methods for anesthesiological applications
  申请人：IMPRIMIS PHARMACEUTICALS, INC.

  公开号：US10166240B2

  公开（公告）日：2019-01-01

  Pharmaceutical compositions and methods for inducing conscious sedation using such compositions are described, the compositions including a benzodiazepine-based compound, a NMDA antagonist, and optionally a β-blocker, antiemetic, an NSAID, and/or an antihistamine medication. Methods for fabricating the compositions and using them for anesthesiological applications are also described.

  本文描述了使用此类组合物诱导清醒镇静的药物组合物和方法，组合物包括苯二氮卓类化合物、NMDA拮抗剂，以及可选的β-受体阻滞剂、止吐药、非甾体抗炎药和/或抗组胺药物。此外，还介绍了制造这些组合物并将其用于麻醉学应用的方法。
• Dextrorphan-derivatives with suppressed central nervous activity
  申请人：Heinrich-Heine-Universität Düsseldorf

  公开号：US10464904B2

  公开（公告）日：2019-11-05

  The invention relates to dextrorphan-derivatives, pharmaceutical compositions and pharmaceutical dosage forms containing such dextrorphan-derivatives as well as the use of those dextrorphan-derivatives and/or compositions for treating and preventing diseases and conditions in man and mammals.

  本发明涉及右旋龙葵素衍生物、药物组合物和含有此类右旋龙葵素衍生物的药物剂型，以及使用这些右旋龙葵素衍生物和/或组合物治疗和预防人类和哺乳动物的疾病和病症。